| Literature DB >> 32746876 |
Dan Jin1, Jiwei Guo2, Yan Wu3, Jing Du3, Lijuan Yang3, Xiaohong Wang4, Weihua Di5, Baoguang Hu6, Jiajia An7, Lingqun Kong8, Lei Pan9, Guoming Su10.
Abstract
An amendment to this paper has been published and can be accessed via the original article.Entities:
Year: 2020 PMID: 32746876 PMCID: PMC7397643 DOI: 10.1186/s13045-020-00942-x
Source DB: PubMed Journal: J Hematol Oncol ISSN: 1756-8722 Impact factor: 17.388
Fig. 2YTHDF3 recognizes m6A modification and promotes cellular growth and migration via YAP upregulation. h The expressions of YAP and its target genes, CTGF and Cyr61, were analyzed by RT-PCR and western blot. n The cellular invasion and migration growths were analyzed by transwell assay. Results were presented as mean ± SD of three independent experiments. *P < 0.05 or **P < 0.01 indicates a significant difference between the indicated groups. NS, not significant
Fig. 6The reduction of YAP m6A modification inhibits tumor growth and enhances DDP sensitivity in vivo. k The tumor nodules from controlvector, METTL3Vector and METTL3shYap groups were treated with PBS or DDP every three days. The protein expression levels of Ki67, ABCG2 and ERCC1were analyzed immunohistochemical staining assays (n = 5). Results were presented as mean ± SD three independent experiments. **P < 0.01 indicates a significant difference between the indicated groups. NS, not significant